You might also like
BioNTech SE is a global next-generation immunotherapy company focused on developing novel medicines for cancer, infectious diseases, and other serious conditions. The company leverages the immune system's power to address diseases with unmet medical needs and significant global health burdens. BioNTech primarily sells mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules.
- COVID-19 Vaccine Revenues - Generates revenue from the sale of COVID-19 vaccines, which is the major contributor to the company's revenue.
- Share of Collaboration Partners' Gross Profit - Receives a share of the gross profit from collaboration partners, primarily Pfizer, based on sales in their territories.
- Direct Product Sales to Customers - Supplies the COVID-19 vaccine directly in territories like Germany and Türkiye.
- Sales to Collaboration Partners - Manufactures and sells products to collaboration partners.
- Research & Development Revenues from Collaborations - Earns revenue from R&D collaborations.
| Name | Position | External Roles | Short Bio | Start Date |
|---|---|---|---|---|
Prof. Ugur Sahin, M.D. ExecutiveBoard | CEO and Co-Founder | None | CEO and Co-Founder of BioNTech, actively involved in strategic and operational development, particularly in oncology and COVID-19 vaccine efforts. | N/A |
Jens Holstein Executive | Chief Financial Officer (CFO) | Non-executive board member at Veracyte Inc. | Joined BioNTech in 2021; previously CFO at MorphoSys AG and held multiple CFO/general management roles at Fresenius SE Group. | 2021 |
Ryan Richardson Executive | Chief Strategy Officer (CSO) | None | Joined BioNTech in 2018; previously worked in healthcare investment banking at J.P. Morgan and as a health economist at IMS Health. | 2018 |
Sean Marett Executive | Chief Business Officer (CBO) and Chief Commercial Officer (CCO) | Chairman of PHMR Ltd; Supervisory board member at AiCuris AG | Joined BioNTech in 2012; led commercialization of the Pfizer-BioNTech COVID-19 vaccine and negotiated key financing rounds and supply agreements. | 2012 |
Sierk Poetting, Ph.D. Executive | Chief Operating Officer (COO) | None | Joined BioNTech in 2014; previously held leadership roles at Novartis and worked as a consultant at McKinsey & Company. | 2014 |
Baroness Nicola Blackwood Board | Supervisory Board Member | Chair of Oxford University Innovation; Chair of Genomics England; Managing Director of Blackwood Intelligence Limited; Member of the House of Lords | Appointed to the Supervisory Board in 2023; brings expertise in science and innovation; holds leadership roles in prominent UK organizations. | 2023 |
Helmut Jeggle Board | Chair of the Supervisory Board | Managing Partner at Salvia GmbH; Supervisory board member at 4SC AG, Tonies SE, AiCuris AG, AFFiRiS AG, APK AG | Chair of BioNTech's Supervisory Board since 2008; instrumental in guiding the company’s strategic direction; previously held roles at Hexal AG and ATHOS KG. | 2008 |
Michael Motschmann Board | Supervisory Board Member | Co-founder and Management Board member at MIG Capital AG; Supervisory board member at APK AG, HMW Emissionshaus AG, Affiris AG; Advisory board member at Efficient Energy GmbH, Temedica GmbH, AMSilk GmbH | Supervisory Board member since 2008; co-founder of MIG Capital AG and active in venture capital investments. | 2008 |
-
Although you have significant ongoing Phase II and III trials, could you elaborate on how you plan to balance the increasing R&D expenses with cost control measures, especially as you invest in assets like BNT327?
-
With regards to your updated guidance at the low end of the range due to low demand and pricing in low and middle income countries, how do you plan to mitigate these challenges and ensure revenue growth in the face of reduced COVID-19 vaccine demand?
-
Given the approximately EUR 600 million accrued for contractual disputes with licensees and collaborators this year, can you provide more clarity on the nature of these disputes and how they might impact future financials?
-
Considering the missed endpoints in the Phase III flu COVID combo program and competitors like Moderna expecting to launch their combo next year, how are you adjusting your strategy to remain competitive in the combination vaccine market?
-
As you expect to maintain or gain market share in key markets this year for your COVID-19 vaccine and believe in improved visibility into vaccine demand, how confident are you in your ability to sustain this given potential shifts in vaccination rates and market dynamics?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Biotheus | 2025 | BioNTech’s acquisition of Biotheus was aimed at strengthening its oncology portfolio with the BNT327 pan-tumor platform; the deal’s total value was $800 million in cash (plus a small portion in ADS) with up to $150 million in performance-based payments, providing full global rights to BNT327, access to an in-house antibody generation platform, and a new R&D hub and manufacturing facility as an indirect Chinese subsidiary. |
InstaDeep | 2023 | BioNTech’s acquisition of InstaDeep involved buying 100% of the remaining shares for approximately €500 million, structured with cash, BioNTech shares, and milestone-based payments, to integrate AI/ML capabilities across industries while InstaDeep continues as a UK-based global subsidiary. |
Medigene | 2022 | In 2022, BioNTech collaborated with and acquired key assets from Medigene, including its next-generation preclinical TCR program (PRAME TCR) and licenses to the PD1-41BB switch receptor, for an upfront payment of EUR 26 million plus milestone, regulatory, and commercial payments, thereby securing exclusive worldwide rights to further TCR immunotherapies. |
Recent developments and announcements about BNTX.
Earnings
New Earnings (Q4 2024)
·1 day agoView full earnings summary →BNTX projects 2025 revenues of €1.7B-€2.2B (down from ~€2.8B in 2024) amid COVID-19 vaccine headwinds. Meanwhile, its BNT327 pipeline shows strong potential with a 70% response rate in early SCLC data. Can oncology offset these near-term declines?